Literature DB >> 12454741

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.

N Mauritzson1, M Albin, L Rylander, R Billström, T Ahlgren, Z Mikoczy, J Björk, U Strömberg, P G Nilsson, F Mitelman, L Hagmar, B Johansson.   

Abstract

To ascertain the frequency of treatment-related acute myeloid leukemias and myelodysplastic syndromes (t-AML/t-MDS) in an unselected series, we have identified all adult cases analyzed in our department from 1976 to 1993. Further aims were to compare karyotypic features of t-AML/t-MDS with de novo AML/MDS, in our material as well as in 5098 unselected, cyto- genetically abnormal, published cases, and to analyze associations between type of prior therapy and karyotype. Among our 372 AML and 389 MDS, 47 (13%) were t-AML and 62 (16%) were t-MDS. Clonal abnormalities were significantly more common in t-AML and t-MDS than in de novo disease (68% vs 50%, P < 0.05 and 84% vs 45%, P < 0.001, respectively). Among the available 4230 AML and 1629 MDS (the present series and published cases), 14% were t-AML and 15% were t-MDS. In t-AML/t-MDS, the number of anomalies and the ploidy levels differed significantly from de novo cases, with complex and hypodiploid karyotypes being more common in t-AML/t-MDS. In t-AML, unbalanced changes in general, t(1;3), der(1;7), 3p-, -5, 5q-, -7, 7q-, t(9;11), t(11;19), t(11q23), der(12p), -17, der(17p), -18, and -21 were significantly more frequent than in de novo AML. In t-MDS, -5, -7, 7q-, 13q-, der(17p), and -18 were significantly more common. Type of prior treatment correlated significantly with number of anomalies in t-AML and with ploidy levels in t-AML/t-MDS. The frequencies of several aberrations varied with type of therapy, eg, 5q- was more frequent in radiotherapy-associated t-MDS, monosomy 7 was more common in t-AML and t-MDS after treatment with alkylators, and t(11q23) in t-AML was associated with topoisomerase II inhibitors. Abnormalities significantly more common in de novo disease were +8 as a sole anomaly, balanced changes in general, t(8;21), t(9;22), t(15;17), inv(16), and t(21q22) in AML, and -Y, 5q-, and 20q- as sole anomalies and +8 in MDS. The results emphasize the strong association between previous genotoxic exposure and karyotypic features.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454741     DOI: 10.1038/sj.leu.2402713

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  57 in total

1.  Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.

Authors:  Isabella Fried; Claudia Bodner; Monika M Pichler; Karin Lind; Christine Beham-Schmid; Franz Quehenberger; Wolfgang R Sperr; Werner Linkesch; Heinz Sill; Albert Wölfler
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.

Authors:  P Gollapudi; V S Bhat; D A Eastmond
Journal:  Mutat Res       Date:  2019-05-15       Impact factor: 2.433

Review 3.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.

Authors:  C Y Ok; R P Hasserjian; P S Fox; F Stingo; Z Zuo; K H Young; K Patel; L J Medeiros; G Garcia-Manero; S A Wang
Journal:  Leukemia       Date:  2013-06-21       Impact factor: 11.528

5.  Clinical Features and Outcomes of 666 Cases with Therapy-Related Myelodysplastic Syndrome (t-MDS).

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-06       Impact factor: 0.900

6.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 7.  Therapy-related B lymphoblastic leukemia with t(4;11)(q21;q23)/AF4-MLL in a patient with mantle cell lymphoma after recent aggressive chemotherapy: a unique case report.

Authors:  Stephanie L Holdener; Lacey Harrington; Johnny Nguyen; Pedro Horna; Elizabeth Sagatys; Bijal Shah; Ling Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia.

Authors:  Maho Ishikawa; Fumiharu Yagasaki; Daisuke Okamura; Tomoya Maeda; Yuichi Sugahara; Itsuro Jinnai; Masami Bessho
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

9.  Two cases of acute myeloblastic leukemia evolving from aplastic anemia.

Authors:  Akihiko Taguchi; Takayuki Tominaga; Yoshitaka Nakamori; Mutsuko Miyazaki; Kenji Shinohara
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

Review 10.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.